{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.47","estimateComment":"The strata information was based on the data obtained from the interactive response technology that was used for randomization.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Only primary and key secondary endpoints were formally tested; this endpoint was not formally tested.","nonInferiorityType":"SUPERIORITY","pValue":"0.2874","paramType":"Odds Ratio (OR)","paramValue":"1.5","statisticalMethod":"stratified Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.89","upperLimit":"32.72","value":"21.6"},{"groupId":"OG001","lowerLimit":"8.30","upperLimit":"24.46","value":"15.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"The MRD-negativity rate was defined as the percentage of participants who achieved a negative MRD result in peripheral blood at the End of Treatment. The threshold used for the analysis was 10\\^-5 cells. MRD status was only analyzed with a threshold of ≤10\\^-5 cells for MRD negativity. The Overall MRD Blood-Evaluable Set included all participants in the Full Analysis Set who received at least 1 dose of study treatment with identifiable clonality in blood samples at Cycle 1 Day 1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with FL and MZL were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL and MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL and MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"NUMBER","populationDescription":"Overall MRD Blood-Evaluable Set. As pre-specified in the Statistical Analysis Plan, the MZL population was a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. The 95% confidence intervals were calculated using the Clopper-Pearson method. Participants who did not have a post-baseline assessment were considered to be \"not assessed,\" but were included in the analysis.","reportingStatus":"POSTED","timeFrame":"up to approximately 34 months","title":"Overall Population: MRD-negativity Rate (at Threshold of 10-5) at End of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}